--- title: "Pharmaron and Eli Lilly have not issued a notice regarding the production cooperation agreement, stating that it is part of normal daily operations" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278960304.md" description: "Pharmaron and Eli Lilly have reached a production cooperation agreement involving the oral small molecule GLP-1 receptor agonist Orforglipron. The company stated that this cooperation is part of its routine operations and has not issued an announcement. Pharmaron collaborates with multiple companies in its daily operations to promote business development and has not identified any insider information that needs to be disclosed" datetime: "2026-03-13T00:18:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278960304.md) - [en](https://longbridge.com/en/news/278960304.md) - [zh-HK](https://longbridge.com/zh-HK/news/278960304.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278960304.md) | [English](https://longbridge.com/en/news/278960304.md) # Pharmaron and Eli Lilly have not issued a notice regarding the production cooperation agreement, stating that it is part of normal daily operations According to a report from Economic News Agency on the 13th, Pharmaron (03759) (Shanghai: 300759) announced that, at the request of the Stock Exchange, it is making a statement regarding recent news reports about the group's production cooperation with a Chinese subsidiary of a leading international pharmaceutical company. After inquiries, it was confirmed that the production cooperation was established and will be conducted as part of the group's routine and general business processes. The group collaborates with various companies across different fields to advance its business development goals. Pharmaron's official Weibo announced that the company has reached a production cooperation agreement with Eli Lilly for the first registered oral small molecule GLP-1 receptor agonist Orforglipron, which caused Pharmaron's stock to rise by 13% during trading. The group stated that it is not aware of any information that needs to be disclosed to prevent its securities from appearing in a false market, nor is it aware of any insider information that needs to be disclosed. (wh) ### 相關股票 - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-HK/quote/562050.CN.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/zh-HK/quote/LLYX.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Direxion Daily LLY Bear 1X Shares (ELIS.US)](https://longbridge.com/zh-HK/quote/ELIS.US.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/zh-HK/quote/ELIL.US.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [PHARMARON (03759.HK)](https://longbridge.com/zh-HK/quote/03759.HK.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [Defiance Daily Target 2X Short LLY ETF (LLYZ.US)](https://longbridge.com/zh-HK/quote/LLYZ.US.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-HK/quote/520500.CN.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [Pharmaron (300759.CN)](https://longbridge.com/zh-HK/quote/300759.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) ## 相關資訊與研究 - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-HK/news/281395595.md) - [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/zh-HK/news/280952509.md) - [Herbst Group LLC Makes New Investment in Eli Lilly and Company $LLY](https://longbridge.com/zh-HK/news/281706190.md) - [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-HK/news/281171668.md) - [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/zh-HK/news/280951810.md)